Pricing Log in Create free account

Aprea Therapeutics, Inc. (APRE) vs Curis, Inc. (CRIS)

Aprea Therapeutics, Inc. and Curis, Inc. are both Biotechnology companies. Aprea Therapeutics, Inc. is the larger, with a market value of $6.2M against $5.7M — 1.1× the size. Curis, Inc. grew revenue faster over the last twelve months: −13.4% against −81.0%. Across the 13 metrics below, Curis, Inc. leads on 7 and Aprea Therapeutics, Inc. on 6.

Valuation

Metric APRE CRIS Biotechnology median
P/E n/m n/m 10.60
P/S 97.70 0.20 9.40
P/B 0.82 0.40 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.65 0.29 0.66
EV/Sales (34.76) (0.27) 9.02
Earnings yield (134.54%) (1,615.91%) (32.88%)
Free cash flow yield (45.64%) (1,649.45%) (23.13%)

Profitability

Metric APRE CRIS Biotechnology median
Gross margin 100.00% 99.52% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (62.83%) 455.35% (51.96%)
Return on assets (53.24%) (87.76%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APRE CRIS Biotechnology median
Revenue growth (TTM) (80.99%) (13.43%) 6.76%
EPS growth (last fiscal year) 17.87% 91.57% 29.88%
Revenue growth, 5-year CAGR — (2.71%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APRE CRIS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.67 0.49 4.97
Net debt to EBITDA 1.11 0.91 1.01

Dividend

Metric APRE CRIS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric APRE CRIS Biotechnology median
Market cap 6.24m 5.67m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack